摘要
目的探讨孟鲁司特钠治疗小儿咳嗽变异性哮喘的临床疗效。方法将100例咳嗽变异性哮喘患儿随机分为治疗组和对照组,每组各50例,治疗组予以孟鲁司特及沙丁胺醇气雾剂治疗,对照组予以辅舒酮、沙丁胺醇气雾剂治疗;比较两组患儿的近期疗效、症状缓解时间和复发率。结果治疗组的有效率为90%,明显高于对照组的56%,两组比较差异有统计学意义(χ2=19.441,P=0.001)。治疗组哮喘症状缓解时间为(5.9±2.6)d,而对照组为(8.0±3.2)d,两组比较差异有统计学意义。治疗结束6个月后,治疗组复发率为12%(6/50),对照组复发率为38%(19/50),两组比较差异有统计学意义(χ2=9.013,P=0.003)。结论孟鲁司特钠治疗小儿咳嗽变异性哮喘疗效确切,有效性高,复发率低,安全性好,值得临床推广。
Objective To explore the clinical curative effect of Montelukast in treatment of cough variant asthama in children. Methods All 100 cases of cough variant asthama were randomly divided into two groups. 50 cases in trial group were treated with albuterol aerosol and montelukast, while the other 50 cases in control group with albuterol aerosol and Flixotide. Then the curative effects, relieving time and recurrent rate of the two groups were compared after treatment. Re- suits The time of clinical relieving of trial group was （5.9_＋2.6） d, which was shorter than the control group （8.0_＋3.2）d. The effective rate of trial group was 90% while 56% in control group （X2=19.441 ,P = 0.001 ）. 6 of 50 cases in trial group recurred after treatment, while 19 of 50 cases recurred in control group （X2=9.013,P = 0.003）.The differences were statis- tically significant. Conclusion Montelukast treatment of cough variant asthama is a safe method of great effect and low re- current rate. It is worth popularizing in clinical treatment.
出处
《中国现代医生》
2012年第31期129-130,共2页
China Modern Doctor
